ITOS

iTeos Therapeutics, Inc. (ITOS) | Rumor.io

iTeos Therapeutics

ITOS

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ITOS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jul 21

iTeos Therapeutics, Inc. ($ITOS) has entered into an agreement to be acquired by Concentra Biosciences for $10.047 in cash per share plus a contingent value right (CVR).
The CVR represents the right to receive a portion of the closing net cash of ITOS in excess of $475 million and 80% of any net proceeds from the disposition of certain product candidates within six months following the closing.
The deal is expected to close quickly, with some analysts predicting a potential upside of $2.00 per share, although the actual value of the CVR is still uncertain.

Generated by AI

Sentiment

Of the messages about ITOS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	61.25% -5.08
Bearish	—	—	—	38.75% +5.08

Bullish· May 28

iTeos Therapeutics ($ITOS) has a high institutional ownership of 96%, indicating strong support from professional investors.
The company has a significant cash reserve of $500 million, which could be a catalyst for further price appreciation, especially considering its market capitalization is less than $400 million.
iTeos Therapeutics is developing cutting-edge cancer immunotherapies, with a strong potential for growth in the kidney disease biotech space, and has already shown a significant gain in value in a short period of time.

Bearish· Sep 16

iTeos Therapeutics' ($ITOS) recent data from GALAXIES Lung-201 was met with negative market reaction, causing its shares to decline.
The company's follow-up interim data raised safety concerns, leading to a significant drop in its stock price.
iTeos Therapeutics' ($ITOS) market value has decreased substantially, with some predicting it will drop below $10.

Generated by AI

Topics

Of the messages about ITOS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	5.88%
Announcements	—	—	—	77.12%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	16.99%

Jul 21

iTeos Therapeutics, Inc. ($ITOS) has entered into an agreement to be acquired by Concentra Biosciences for $10.047 in cash per share plus a contingent value right (CVR).
The CVR represents the right to receive 100% of the closing net cash in excess of $475 million and 80% of any net proceeds from the disposition of certain product candidates within six months following the closing.
The acquisition is expected to close in Q3 2025, with Concentra Biosciences acquiring iTeos Therapeutics as a subsidiary.

Generated by AI

Community

Of the messages about ITOS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	63.11%
Newcomers	0%	0%	0%	36.89%

Regulars· May 28

iTeos Therapeutics, Inc. ($ITOS) is winding down its operations, with a cash pile of $16 per share to be distributed to investors.
The company's decision to stop its operations is a demonstration of discipline, as only a few biotechs, including iTeos, have shown this kind of financial responsibility.
iTeos' board has determined that winding down operations will maximize shareholder value, and the company will stop its projects and activities.

Newcomers· May 28

iTeos Therapeutics has announced plans to wind down its operations, sell its assets, and return a significant portion of its cash pile to investors.
The company's stock price has been volatile, with some users averaging up and expecting a 15-20% return within 2-6 months.
iTeos Therapeutics' experimental cancer treatments and obesity program are being explored for potential sales, and the company's stock price has seen a nearly 100% gain in a month.

Generated by AI

Also Discussed

Investors talking about ITOS also mention

#	Name	Attention
1	Arcus Biosciences, Inc.RCUS	0%new
2	Galapagos NV American Depositary ReceiptGLPG	0%0
3	PSTX - Poseida Therapeutics, Inc.	——
4	Sutro Biopharma Inc.STRO	0%new
5	ALX Oncology Holdings Inc.ALXO	0%0
6	DAWN - Day One Biopharmaceuticals, Inc.	——
7	IGMS - IGM Biosciences, Inc.	——
8	Biohaven Ltd.BHVN	0%-0.01
9	Arvinas, Inc.ARVN	0%+0
10	Mereo BioPharma Group plc ADRMREO	0.01%-0.01